The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

What changed in 2026, by region — does this still hold?

This is a generated summary. It shows the 5 most-liked posts from a topic of 26, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
FP
forest_plotTL3Evidence synthesis Solution15 Apr 2026#3

Nothing here is legal advice, and in this subcategory that caveat is doing real work rather than sitting decoratively at the end.

18 likes 3mo
MS
m.strand_rphTL3Pharmacist8 May 2026#7

Everything in post #6 holds. The case it does not cover is the one I have.

Where a compound is approved under a different trade name in another market, searching the local name finds documents the English name does not.

25 likes 3mo
ZC
z.cardosoTL222 May 2026#10

Picking up post #9: that is the part I would want checked first.

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

26 likes 2mo
DV
d.vestergaardTL226 Jun 2026#18
n.villalobos, post #4: The opening post answers the question as asked. The question underneath it is different. Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks. Go to post

The most useful thing anyone can add to a thin regional thread is what the official source says and where it is, rather than what happened to them.

Scoping that to what I have actually seen rather than what I have read.

29 likes in reply to #4 1mo
HK
h.kimaniTL223 Jul 2026#25

Where a jurisdiction has published guidance for clinicians, that document usually answers the practical questions better than any consumer-facing page.

28 likes 5d

Read the full topic (26 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Prescription portability between countries
Prescription portability between countries — setting out what I have, and where I think it stops being reliable. Asking about prescription portability between countries directly, because I have read four…
SGTLDCIAL+104 114 6.1k 3h
Availability by country, dated, with primary sources
On the subject in the title: Availability by country, dated, with primary sources Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
KOSKJNNSMS+72 81 6.9k 8mo
Cross-border purchase within the EU: the actual rules
Cross-border purchase within the EU: the actual rules Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on cross-border…
SCMIBVET+6 10 41k 11mo
Personal import allowances, compared
On the subject in the title: Personal import allowances, compared Working notes rather than a conclusion. I have spent a fortnight trying to pin personal import allowances down and I want to set out where I…
BANNKAKSC+5 9 3.2k 7mo
Prescription portability between countries — the long version
On the subject in the title: Prescription portability between countries — the long version Working notes rather than a conclusion. A narrow question about Prescription portability between countries,…
HVMRSC 2 182 21h

Related topics — sharing the tags personal import, MHRA, EMA

TopicParticipantsRepliesViewsActivity
[2026 update] EU-wide position versus national implementation
On the subject in the title: EU-wide position versus national implementation Working notes rather than a conclusion. A methods question rather than a substantive one, about eu-wide position versus national…
FIANDT 2 54k 19mo
What a regulator's shortage notice actually authorises
What a regulator's shortage notice actually authorises — that is the question, and I have not found it answered plainly anywhere I have looked. Asking what a regulator's document actually says, since the…
BESCAAQLSG+8 12 15k 17h
Pharmaceutical compounding rules, summarised from primary sources — a second dataset
Posting this under the heading it deserves: Pharmaceutical compounding rules, summarised from primary sources — a second dataset Everything below is what sits behind that. Asking what a regulator's document…
CRDPICCDJB+50 56 780 8mo
EMA product information as a primary source — does this still hold?
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it. Something about EMA product information does…
CCSGRWIAII+127 150 41k 20mo
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A narrow question about NHS criteria, deliberately…
RLJIWTGBST+11 15 11k 9mo